LivaNova PLC reports developments as a global medical technology company focused on selected neurological and cardiac conditions. Company news commonly covers revenue results and guidance, performance in its Cardiopulmonary and Epilepsy businesses, and updates tied to medical-device commercialization and clinical evidence.
Recurring product themes include VNS Therapy for drug-resistant epilepsy, real-world evidence from the CORE-VNS study, and obstructive sleep apnea technology using proximal hypoglossal nerve stimulation. Updates also include FDA regulatory decisions, including premarket approval for the aura6000 System, investor conference appearances, and business update calls.
LivaNova PLC has announced the first patient implanted in its IDE clinical study, OSPREY, aimed at evaluating the effectiveness of its aura6000™ System for treating moderate to severe obstructive sleep apnea (OSA). Conducted at around 20 sites in the U.S., the study plans to enroll up to 150 patients. The aura6000 System is designed to stimulate the hypoglossal nerve and may offer an alternative to CPAP therapy, which many patients find restrictive.
LivaNova PLC (Nasdaq: LIVN) reported a modest 0.2% increase in Q4 2021 worldwide sales from continuing operations, totaling $270.1 million. Excluding the divested Heart Valves business, sales rose by 10.1%. Adjusted diluted earnings per share (EPS) was $0.57, down from $0.70 in Q4 2020. For full-year 2021, total sales reached $1.035 billion, with a 10.8% increase year-over-year. LivaNova anticipates 2022 sales growth of 3-5% and adjusted EPS between $2.50-$2.80. Notably, the company is currently involved in a significant litigation case in Italy.
LivaNova PLC (NASDAQ: LIVN) is set to host a conference call on February 23, 2022, at 1 p.m. London time to discuss its fourth-quarter and full-year 2021 results. The results will be released prior to the call. Investors can access the call via audiocast on the LivaNova website or by phone. The company emphasizes its commitment to innovative medical technologies aimed at improving patient outcomes worldwide. For more details, visit www.livanova.com.
LivaNova PLC (NASDAQ:LIVN), a leader in medical technology, will participate in the American Epilepsy Society Annual Meeting from December 3-7 in Chicago. The company plans to present seven scientific posters highlighting its VNS Therapy System, which has been effective in treating drug-resistant epilepsy for over 25 years. Presentations will cover patient profiles, healthcare costs, and optimal treatment strategies. LivaNova demonstrates its dedication to neuromodulation research and collaboration with independent investigators to improve outcomes for epilepsy patients.
LivaNova PLC (LIVN) announced its participation in the 4th International Brain Stimulation Conference from December 6-9 in Charleston, S.C. The company will showcase its advancements in VNS Therapy® for treatment-resistant depression. LivaNova is conducting the RECOVER study to evaluate VNS Therapy's effectiveness for difficult-to-treat depression.
LivaNova PLC (NASDAQ:LIVN) announced that CEO Damien McDonald will participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference on December 1, 2021. This event showcases LivaNova's commitment to innovation in medical technology. The pre-recorded discussion will be available on LivaNova's website, remaining accessible for 90 days. With nearly 3,000 employees and a presence in over 100 countries, LivaNova aims to deliver life-changing medical technologies for patients worldwide. For more details, visit www.livanova.com.
LivaNova PLC (NASDAQ:LIVN) announced a ruling from the Court of Appeal of Milan, requiring the company to pay €453 million (around $519 million) for environmental liabilities linked to a former parent company, SNIA. LivaNova disputes the decision and plans to appeal to the Italian Supreme Court. This civil action may impact LivaNova's financial standing but the outcome of the appeal regarding joint liability is pending. The company maintains a strong global presence, operating in over 100 countries.
LivaNova PLC (NASDAQ:LIVN), a leading medical technology company, announces its CEO, Damien McDonald, will present at two significant healthcare conferences: the Stifel 2021 Virtual Healthcare Conference on November 17 at 10 a.m. Eastern and the Jefferies 2021 London Healthcare Conference on November 18 at 3 a.m. Eastern. Both presentations will be accessible via webcasts on LivaNova’s website, with replays available for 90 days. LivaNova, headquartered in London, employs around 3,000 people and operates in over 100 countries.
LivaNova PLC (NASDAQ:LIVN) announced a virtual Investor Day on December 7 from 8 a.m. to 12 p.m. CT. Executive leadership will present the long-range business plan aimed at maximizing growth and shareholder value. Additionally, the event will include overviews of the company’s franchises and strategic pipeline initiatives, with opportunities for Q&A sessions. Interested attendees can register via the LivaNova website. Following the event, a replay and presentation materials will be available online for one year.
LivaNova PLC (NASDAQ: LIVN) reported a 5.5% increase in third-quarter 2021 sales, reaching $253.2 million. Excluding the divested Heart Valves business, sales grew by 15.7%. Adjusted diluted EPS was $0.68, up from $0.38 in Q3 2020. The company raised 2021 guidance, projecting 8-11% net sales growth and adjusted EPS of $2.00 to $2.10. Operating income rose significantly to $17.9 million, with adjusted operating income at $47.9 million, a 49.1% increase. LivaNova also improved its cash flow and financial flexibility through an equity offering, retiring a $450 million term loan.